BICARA THERAPEUTICS INC. - COMMON STOCK

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 Apr 2025 10:00:02 By Nasdaq GlobeNewswire

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

27 Mar 2025 07:30:59 By Nasdaq GlobeNewswire

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

25 Mar 2025 16:45:55 By Nasdaq GlobeNewswire

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

24 Feb 2025 16:01:38 By Nasdaq GlobeNewswire

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

11 Feb 2025 16:01:21 By Nasdaq GlobeNewswire

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

27 Jan 2025 08:00:15 By Nasdaq GlobeNewswire

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 07:30:49 By Nasdaq GlobeNewswire

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

11 Nov 2024 16:01:02 By Nasdaq GlobeNewswire

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 Sep 2024 16:01:00 By Nasdaq GlobeNewswire